Christopher K. Daugherty

4.8k total citations · 2 hit papers
87 papers, 3.4k citations indexed

About

Christopher K. Daugherty is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Economics and Econometrics. According to data from OpenAlex, Christopher K. Daugherty has authored 87 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Public Health, Environmental and Occupational Health, 24 papers in Pediatrics, Perinatology and Child Health and 23 papers in Economics and Econometrics. Recurrent topics in Christopher K. Daugherty's work include Palliative Care and End-of-Life Issues (24 papers), Childhood Cancer Survivors' Quality of Life (21 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Christopher K. Daugherty is often cited by papers focused on Palliative Care and End-of-Life Issues (24 papers), Childhood Cancer Survivors' Quality of Life (21 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Christopher K. Daugherty collaborates with scholars based in United States, Canada and Australia. Christopher K. Daugherty's co-authors include Fay J. Hlubocky, Mark J. Ratain, Kristen Wroblewski, David Cella, Elisa J. Gordon, Jonas A. de Souza, Bonnie J. Yap, Paul R. Helft, Jeremy O’Connor and Victoria Blinder and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Christopher K. Daugherty

86 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

2016 585 citations Bonnie J. Yap, Kristen Wroblewski et al. profile →
The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

2014 445 citations Bonnie J. Yap, Fay J. Hlubocky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher K. Daugherty United States	28	1.5k	1.1k	961	841	687	87	3.4k
Steven B. Clauser United States	34	1.0k 0.7×	814 0.8×	449 0.5×	1.1k 1.4×	1.7k 2.5×	94	3.9k
Mary S. McCabe United States	34	2.0k 1.4×	624 0.6×	1.4k 1.5×	747 0.9×	2.5k 3.6×	87	4.5k
Laura P. Forsythe United States	32	1.2k 0.8×	757 0.7×	905 0.9×	1.5k 1.7×	1.7k 2.5×	51	4.3k
Fay J. Hlubocky United States	25	940 0.6×	989 0.9×	654 0.7×	770 0.9×	684 1.0×	99	2.8k
Janet S. de Moor United States	33	1.0k 0.7×	1.8k 1.7×	1.0k 1.0×	536 0.6×	2.3k 3.4×	80	4.8k
Una Macleod United Kingdom	34	848 0.6×	365 0.3×	328 0.3×	937 1.1×	2.1k 3.1×	104	3.7k
Dana S. Wollins United States	24	1.2k 0.8×	687 0.7×	777 0.8×	381 0.5×	1.8k 2.6×	39	4.0k
Maria Pisu United States	35	858 0.6×	1.1k 1.0×	657 0.7×	709 0.8×	1.4k 2.0×	207	4.2k
Ryan David Nipp United States	37	1.8k 1.2×	658 0.6×	927 1.0×	478 0.6×	2.3k 3.4×	243	4.5k
Larissa Nekhlyudov United States	41	1.4k 1.0×	607 0.6×	1.0k 1.1×	668 0.8×	3.1k 4.5×	174	5.1k

Countries citing papers authored by Christopher K. Daugherty

Since Specialization

Citations

This map shows the geographic impact of Christopher K. Daugherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher K. Daugherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher K. Daugherty more than expected).

Fields of papers citing papers by Christopher K. Daugherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher K. Daugherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher K. Daugherty. The network helps show where Christopher K. Daugherty may publish in the future.

Co-authorship network of co-authors of Christopher K. Daugherty

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher K. Daugherty. A scholar is included among the top collaborators of Christopher K. Daugherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher K. Daugherty. Christopher K. Daugherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gurfinkel, Dennis, Caroline Tietbohl, Brooke Dorsey Holliman, et al.. (2024). Financial Toxicity, Health-Related Quality of Life, and Medication Adherence Patient-Reported Outcomes (PROs) in Patients with Chronic Lymphocytic Leukemia (CLL) on First-Line Oral Oncolytics. Blood. 144(Supplement 1). 2354–2354.

Hlubocky, Fay J., Banu Symington, Daniel C. McFarland, et al.. (2021). Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization’s Response for Readiness, Mitigation, and Resilience. JCO Oncology Practice. 17(7). 365–374. 51 indexed citations

Hlubocky, Fay J., Greg A. Sachs, Eric R. Larson, et al.. (2018). Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?. Journal of Clinical Oncology. 36(24). 2483–2491. 13 indexed citations

Hlubocky, Fay J., et al.. (2017). The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG).. Journal of Clinical Oncology. 35(15_suppl). 10115–10115. 2 indexed citations

Polite, Blasé N., Fay J. Hlubocky, James J. Dignam, et al.. (2016). An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. Journal of Racial and Ethnic Health Disparities. 4(2). 140–148. 6 indexed citations

Daugherty, Christopher K., et al.. (2015). Is it ethical to enroll a patient in a hepatitis C virus clinical trial when current standard of care is highly effective and safe?. Clinical Liver Disease. 6(5). 120–121. 1 indexed citations

Nathan, Paul C., Christopher K. Daugherty, Kristen Wroblewski, et al.. (2013). Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. Journal of Cancer Survivorship. 7(3). 275–282. 143 indexed citations

Spill, Gayle R., Fay J. Hlubocky, & Christopher K. Daugherty. (2012). Oncologists' and Physiatrists' Attitudes Regarding Rehabilitation for Patients With Advanced Cancer. PM&R. 4(2). 96–108. 37 indexed citations

Ishida, Yasushi, et al.. (2012). Physician Preferences and Knowledge Regarding the Care of Childhood Cancer Survivors in Japan: A Mailed Survey of the Japanese Society of Pediatric Oncology. Japanese Journal of Clinical Oncology. 42(6). 513–521. 10 indexed citations

10.

Zafar, S. Yousuf, David C. Currow, Christopher K. Daugherty, & Amy P. Abernethy. (2010). Standards for Palliative Care Delivery in Oncology Settings. The Cancer Journal. 16(5). 436–443. 9 indexed citations

11.

Daugherty, Christopher K., Mark J. Ratain, Ezekiel J. Emanuel, Ann T. Farrell, & Richard L. Schilsky. (2008). Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials. Journal of Clinical Oncology. 26(8). 1371–1378. 40 indexed citations

12.

Bradbury, Angela R., et al.. (2008). Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 148C(1). 70–77. 27 indexed citations

13.

Bradbury, Angela R., Linda Patrick‐Miller, Shelly Cummings, et al.. (2008). Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psycho-Oncology. 18(2). 200–208. 41 indexed citations

14.

Johnson, Julie K., et al.. (2007). Housestaff and Medical Student Attitudes Toward Medical Errors and Adverse Events. The Joint Commission Journal on Quality and Patient Safety. 33(8). 493–501. 40 indexed citations

15.

Artz, Andrew, Daniel A. Pollyea, Masha Kocherginsky, et al.. (2006). Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 12(9). 954–964. 92 indexed citations

16.

Daugherty, Christopher K., et al.. (2004). Trusting God and medicine: Spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psycho-Oncology. 14(2). 135–146. 51 indexed citations

17.

Odenike, Olatoyosi, Ronald Sobecks, Linda Janisch, et al.. (2004). A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemotherapy and Pharmacology. 54(6). 553–561. 5 indexed citations

18.

Gordon, Elisa J. & Christopher K. Daugherty. (2003). ‘Hitting you over the head’: Oncologists’ disclosure of prognosis to advanced cancer patients. Bioethics. 17(2). 142–168. 219 indexed citations

19.

Daugherty, Christopher K., et al.. (2001). Preliminary Experience with a New Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia. Leukemia & lymphoma. 41(3-4). 297–307. 14 indexed citations

20.

Daugherty, Christopher K.. (1999). Ethical Issues in the Development of New Agents. Investigational New Drugs. 17(2). 145–153. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact